• Noncompetitive Inhibition of Human PON1 by Primidone and Oth

  2026-07-08

  This study systematically evaluates how clinically used antiepileptic drugs, including Primidone (Mysoline), inhibit human serum paraoxonase-1 (hPON1) in vitro. The findings clarify the noncompetitive inhibition mechanism, report precise inhibition constants, and highlight implications for oxidative stress and cardiovascular risk in epilepsy management.

• Viral Modulation of RIPK3 Degradation and Necroptosis in Inf

  2026-07-08

  Liu et al. identify a class of orthopoxvirus proteins that actively induce the degradation of the necroptosis adaptor RIPK3, suppressing necroptosis and modulating virus-induced inflammation. These findings elucidate a unique viral immune evasion mechanism and provide an experimental framework for dissecting host-pathogen interactions and regulated cell death.

• TAI-1 Hec1 Inhibitor: Transforming Cancer Cell Assays

  2026-07-07

  TAI-1, a first-in-class Hec1 inhibitor, delivers nanomolar potency for targeted apoptotic cell death induction and robust cancer cell proliferation inhibition. Its synergy with standard chemotherapies and adaptability to advanced organoid models set a new benchmark for precision oncology research.

• JHU-083: Advancing Glutaminase Pathway Research Protocols

  2026-07-07

  JHU-083, a potent 6-diazo-5-oxo-L-norleucine precursor, enables selective glutaminase inhibition in cerebral CD11b cells, redefining workflows for neurotoxicity and experimental cerebral malaria models. This article delivers actionable protocols, troubleshooting strategies, and contextualizes JHU-083’s role in light of new GSTA1-glutathione research.

• Cyclopamine: Precision Hedgehog Signaling Inhibition in Canc

  2026-07-06

  Cyclopamine enables targeted disruption of the Hedgehog pathway, empowering cancer and developmental biology workflows with high specificity and reproducibility. Recent studies demonstrate its unique synergy with molecular targets like APOC1, guiding protocol enhancements for apoptosis induction and tumor growth inhibition.

• Biomimetic Chromatography Advances Pulmonary Drug Permeabili

  2026-07-06

  This study rigorously benchmarks biomimetic chromatographic methods—immobilised artificial membrane chromatography (IAM-LC) and open-tubular capillary electrochromatography (OT-CEC)—for modeling lung permeability of pharmaceuticals. The findings clarify method robustness, correlation with physicochemical properties, and practical suitability for high-throughput screening in respiratory drug development.

• CK2 and ERK8 Inhibitor: Expanding Molecular Tools for Protei

  2026-07-05

  Explore how the small molecule inhibitor 2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid uniquely empowers protein phase separation research. This article delivers new, practical insight into kinase targeting and biochemical assay design using APExBIO’s CK2 and ERK8 inhibitor.

• Pterostilbene Preserves Blood–Brain Barrier After Ischemic S

  2026-07-04

  This study demonstrates that pterostilbene protects the blood–brain barrier (BBB) following cerebral ischemia/reperfusion by targeting both early cytoskeletal changes and late extracellular matrix degradation. These dual mechanisms reveal new therapeutic approaches for maintaining BBB integrity and mitigating ischemic stroke injury.

• Biomimetic Nanoplatform Synergizes Photothermal and Immune T

  2026-07-03

  A recent ACS Nano study presents a dendritic mesoporous silica nanoplatform engineered for targeted, multimodal treatment of metastatic triple-negative breast cancer (TNBC). By integrating photothermal ablation with immune remodeling, the approach achieves synergistic tumor targeting and immune activation, offering a promising alternative to conventional therapies.

• MLN4924 HCl Salt: Precision NEDD8-Activating Enzyme Inhibiti

  2026-07-03

  MLN4924 HCl salt empowers researchers to dissect neddylation pathway inhibition with unmatched specificity, enabling breakthroughs in cancer biology and viral immunity studies. This article delivers actionable workflows, troubleshooting insights, and comparative advantages for deploying this NEDD8-activating enzyme inhibitor across complex cellular models.

• MLN4924 HCl Salt: Precision NEDD8-Activating Enzyme Inhibiti

  2026-07-02

  MLN4924 HCl salt empowers researchers with reliable, highly selective inhibition of the NEDD8-activating enzyme, unlocking new experimental avenues in cancer biology and viral immunity. Integrating robust protocol guidance and troubleshooting, this article translates cutting-edge findings into actionable workflows—bridging fundamental ubiquitination research with translational models.

• LLC-PK1-MOCK/MDR1 Model Enhances BBB Permeability Prediction

  2026-07-02

  The study establishes a high-throughput in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells, integrating lysosomal trapping correction to improve permeability predictions. This approach shows strong concordance with in vivo brain distribution, supporting more efficient CNS drug screening.

• Unraveling Assay Precision: HyperFluor™ 488 Goat Anti-Human

  2026-07-01

  Explore how the HyperFluor 488 Goat Anti-Human IgG (H+L) Antibody empowers translational research with unparalleled assay precision and flexibility. This article goes beyond protocol tips, providing a scientific deep dive into the molecular mechanisms and decision-making behind advanced immunodetection workflows.

• Bufalin Targets STK33 to Inhibit Triple-Negative Breast Canc

  2026-07-01

  This study uncovers Serine/Threonine Kinase 33 (STK33) as a direct molecular target of Bufalin in triple-negative breast cancer (TNBC). By elucidating the mechanism by which Bufalin destabilizes STK33 and suppresses tumor proliferation, the research advances understanding of targeted therapies for TNBC and offers a framework for preclinical evaluation of cardiotonic steroids in oncology.

• Spp1 Drives Kidney Fibrosis via TGF-β/Smad: Single-Cell Insi

  2026-06-30

  A recent iScience study uncovers Spp1 as a pivotal modulator of kidney fibrosis, acting through the TGF-β/Smad signaling pathway. By leveraging single-cell sequencing and functional assays, the research highlights Spp1's impact on fibroblast-to-myofibroblast transition, offering new targets for antifibrotic strategies.

15850 records 1/1057 page Next 12345 下5页 Last page